Abstract
Summary
Osteopontin (OPN)-deficient mice are resistant to ovariectomy-induced osteoporosis. Therefore, we hypothesized that women with OPN overexpression may show less resistance to postmenopausal osteoporosis. In this study, we first demonstrated that serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.
Introduction
Animal studies indicate that OPN-deficient mice are resistant to ovariectomy-induced osteoporosis.
Methods
From 2004 to 2006, 124 women over the age of 45 were enrolled in a menopausal group, while another 95 women, from 25 to 45 years of age with regular menstruation, were enrolled into a childbearing age group. The serum concentrations of OPN were calculated using the enzyme-link immunosorbent assay method, and bone mineral densities were determined with dual energy X-ray absorptiometry.
Results
Serum OPN levels had a significant positive correlation with age (menopausal group, p < 0.0001) and a negative correlation with body weight, height, hip bone mineral density, and T-scores in the menopausal group. In contrast, there was a positive correlation with the E2 concentration and height, but there was no significant association with the above variables in the childbearing age group. Additionally, high serum OPN levels (>14.7 ng/ml) was a significant risk factor causing menopausal osteoporosis (odds ratio = 2.96, 95% confidence interval, 1.055–8.345).
Conclusion
Serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.
Similar content being viewed by others
References
Ishijima M, Ezura Y, Kunikazu T, Rittling SR, Kurosawa H, Denhardt DT, Emi M, Nifuji A, Noda M (2006) Osteopontin during tail-suspension-induced bone loss. Exp Cell Res 312:3075–3083
Rittling SR, Matsumoto HN, Mckee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101–1111
Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113
Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 96:8156–8160
Asou Y, Rittling SR, Yoshitake H, Tsuji K, Shinomiya K, Nifuji A, Denhardt DT, Noda M (2001) Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142:1325–1332
Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M (2001) Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276:13065–13071
Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M (2002) Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A 99:4556–4561
Morinobu M, Ishijima M, Rittling SR, Tsuji K, Yamamoto H, Nifuji A, Denhardt DT, Noda M (2003) Osteopontin expression in osteoblasts and osteocytes during bone formation under mechanical stress in the calvarial suture in vivo. J Bone Miner Res 18:1706–1715
Kitahara K, Ishijima M, Rittling SR, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2003) Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144:2132–2140
Chen Y, Bal BS, Gorski JP (1992) Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 267:24871–24878
Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265
MacNeli RL, Berry J, D'ErricoJ SC, Piotrowski B, Somerman MJ (1995) Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. Connect Tissue Res 33:1–7
Horton MA, Nesbit MA, Helfrich MH (1995) Interaction of osteopontin with osteoclast integrins. Ann N Y Acad Sci 760:190–200
Giachelli CM, Liaw L, Murry CE, Schwartz S, Almeida MM (1995) Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 760:109–126
Liaw L, Lombardi DM, Almeida MM, Schwartz SM, DeBlois D, Giachelli CM (1997) Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 17:188–193
Pichler R, Giachelli CM, Young B, Alpers CE, Couser WG, Johnson RJ (1995) The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Miner Electrolyte Metab 21:317–327
Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L (1995) Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci 760:83–100
Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509–512
Kennedy OD, Brennan O, Rackard SM, Staines A, O'Brien FJ, Taylor D, Lee TC (2009) Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J Orthop Res 27:303–309
Shapses SA, Cifuentes M, Spevak L, Chowdhury H, Brittingham J, Boskey AL, Denhardt DT (2003) Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calcif Tissue Int 73(1):86–92
Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Ezura Y, Noda M (2007) Osteopontin is required for mechanical stress-dependent signals to bone marrow cells. J Endocrinol 193(2):235–243
Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB (2007) Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res 83(1):136–144
McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393
Malaval L, Wade-Guéye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amédée J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205(5):1145–1153
Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 31:92–102
Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodeling rather than in inflammation in ankylosing spondylitis. Rheumatology 47:1775–1779
Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9(1):59–67
Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer. Lancet Oncol 6:757–764
Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, Dunst J, Flentije M, Bache M (2006) Plasma osteopontin lecels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 207:1–6
Eastell R (2003) Pathogenesis of postmenopausal osteoporosis. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. American Society for Bone and Mineral Research, Washington (DC), pp 314–316
Recker R, Lappe J, Davies K, Heaney R (2000) Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 15:1965–1973
Abrahamsen B, Nissen N, Hermann AP, Hansen B, Bärenholdt O, Vestergaard P, Tofteng CL, Pors Nielsen S (2002) When should densitometry be repeated in healthy peri- and postmenopausal women? The Danish osteoporosis prevention study. J Bone Miner Res 17:2061–2067
Li Y, Li A, Yang X, Weitzmann MN (2007) Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100(6):1370–1375
Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J (2002) Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 17(8):1486–1497
Rajachar RM, Truong AQ, Giachelli CM (2008) The influence of surface mineral and osteopontin on the formation and function of murine bone marrow-derived osteoclasts. J Mater Sci Mater Med 19(10):3279–3285
Ono N, Nakashima K, Rittling SR, Schipani E, Hayata T, Soma K, Denhardt DT, Kronenberg HM, Ezura Y, Noda M (2008) Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem 283(28):19400–19409
Namkung-Matthai H, Appleyard R, Jansen J (2001) Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. Bone 28:80–86
Roseleen M, McCann GC, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393
D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G (2006) Receptor activator of NF (Kappa) B ligand/osteoprotegerin (RANKL/OPG) system and osteoportnin (OPN) serum levels in a population of apullian postmenopausal women. Panminerva Med 48(4):215–221
Vondracek SF, Hansen LB, McDermott MT (2009) Osteoporosis risk in premenopausal women. Pharmacotherapy 29(3):305–317
Bischoff L, Derk CT (2008) Premenopausal osteoporosis. Minerva Med 99(1):55–63
Hamel ME, Sebaldt RJ, Siminoski K, Adachi JD, Papadimitropoulos AP, Goldsmith CH (2005) Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. Osteoporos Int 16:208–215
Solomon DH, Levin E, Helfgott SM (2000) Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. J Rheumatol 27:1496–1500
Pressman A, Forsyth B, Ettinger B, Tosteson ANA (2001) Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int 12:337–342
Hajcsar EE, Hawker G, Bogoch ER (2000) Investigation and treatment of osteoporosis in patients with fragility fractures. Can Med Assoc J 163:819–822
Ridout R, Hawker GA (2000) Use of bone densitometry by Ontario family physicians. Osteoporos Int 11:393–399
Papa LJ, Weber BE (1997) Physician characteristics associated with the use of bone densitometry. J Gen Intern Med 12:781–783
Acknowledgments
This work was supported by grants from National Science Council (NSC97-2314-B-040-010-MY3) of Taiwan, People's Republic of China.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
I.-C. Chang and T.-I. Chiang equally contributed to this study.
The authors have no proprietary or financial interest in any material or device mentioned.
Rights and permissions
About this article
Cite this article
Chang, IC., Chiang, TI., Yeh, KT. et al. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21, 1401–1409 (2010). https://doi.org/10.1007/s00198-009-1107-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-009-1107-7